Clinical Trial Update: Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating valsartan for attenuation of disease evolution in early sarcomeric hypertrophic cardiomyopathy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• VALSARTAN (Valsartan)

Snippet

Sponsor: Carelon Research | Conditions: Hypertrophic Cardiomyopathy | Phase 2 | Status: COMPLETED